This project will establish an open-source network to share new cellular engineering platforms across manufacturing facilities; expand our non-viral engineering approaches to improve product safety and efficacy; and formalize our GMP training programs for students, staff, and leadership positions. This project will implement new non-viral engineering platforms to improve cell therapy safety and efficacy, and will establish an open-source network to freely share these platforms across California manufacturing facilities. This approach is expected to significantly reduce development costs, accelerate the generation of new products, and expand patient access to next generation cell and gene therapies.